Evidence map›Paper›PMID 30069688›Full record

ArticleCancer immunology, immunotherapy : CII2018

3-Day monocyte-derived dendritic cells stimulated with a combination of OK432, TLR7/8 ligand, and prostaglandin E

Dag Heiro Yi, Nadine Stetter, Kjerstin Jakobsen, Roland Jonsson, Silke Appel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dag Heiro YiBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway.
Nadine StetterBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway.
Kjerstin JakobsenBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway.
Roland JonssonBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway.
Silke AppelBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, 5021, Bergen, Norway. silke.appel@uib.no.ORCID http://orcid.org/0000-0002-2199-2315
University of Bergen · NOHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous trials using dendritic cell (DC)-based vaccinations for the treatment of cancer are being carried out. However, an improvement of the quality of DC used is highly warranted. We here generated human monocyte-derived dendritic cells using a 3 day protocol and stimulated the cells using a combination of OK432 (Picibanil), TLR7/8 ligand CL097, and reduced amounts of prostaglandin (PG)E

Indexed as

ImmunotherapyAntineoplastic AgentsCell DifferentiationCell MovementCells, CulturedCytokinesDendritic CellsDinoprostoneHumansLigandsMonocytesNeoplasmsOxytocicsPicibanilToll-Like Receptor 7Toll-Like Receptor 8Antineoplastic AgentsCytokinesDinoprostoneLigandsOxytocicsPicibanilTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8CancerDendritic cellsImmunotherapyOK432Pro-inflammatory cytokines

Identifiers

PMID30069688
PMCPMC11028251
OpenAlexW2885269614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.